Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 in eosinophilic asthma
NCT06441812Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-1703 in eosinophilic asthma (EA), sponsored by Hengrui Therapeutics. Primary endpoint: Adverse Events at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
SHR-1703
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT06441812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441812.